Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors

Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors

Blog Article

Immune checkpoint inhibitors (ICIs) represent a major breakthrough in cancer therapy.Immune-related adverse events (irAEs) may occur during treatment due to their unique mechanism of action.Dermatologic toxicities appear to be one of the Thinners most prevalent irAEs.

The Batteries - Chargers most common symptoms are maculopapular rash and pruritus.Serious dermatologic AEs, including Stevens-Johnson syndrome and toxic epidermal necrolysis, are rare.In this review, we summarized guidelines of management of immunotherapy-related toxicities and case reports, and proposed treatment recommendation.